KYMERA THERAPEUTICS, INC. Stock-Based Compensation
KYMERA THERAPEUTICS, INC. (KYMR) reported Stock-Based Compensation of $34.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $18.94M, a 22.85% increase year-over-year.
- KYMERA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $16.01M, a 12.46% increase year-over-year.
- KYMERA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $14.45M, a 4.74% increase year-over-year.
- KYMERA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $15.80M, a 6.03% increase year-over-year.
- KYMERA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $59.90M, a 8.89% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $55.01M, a 27.58% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $43.12M, a 21.53% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $35.48M, a 42.08% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $34.95M 10-Q · filed 2026-08-05 | $49.40M derived: sum of 3 quarters · filed 2026-08-05 | $65.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $16.01M 10-Q · filed 2026-04-30 | $30.46M derived: sum of 2 quarters · filed 2026-04-30 | $46.26M derived: sum of 3 quarters · filed 2026-04-30 | $61.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $14.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $30.25M derived: sum of 2 quarters · filed 2026-02-26 | $45.67M derived: sum of 3 quarters · filed 2026-08-05 | $59.90M 10-K · filed 2026-02-26 |
| 2025-09-30 | $15.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $31.22M derived: sum of 2 quarters · filed 2026-08-05 | $45.45M 10-Q · filed 2025-11-04 | $59.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $15.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $29.65M 10-Q · filed 2026-08-05 | $43.45M derived: sum of 3 quarters · filed 2026-08-05 | $58.35M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $14.23M 10-Q · filed 2026-04-30 | $28.03M derived: sum of 2 quarters · filed 2026-04-30 | $42.94M derived: sum of 3 quarters · filed 2026-04-30 | $57.28M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $13.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $28.70M derived: sum of 2 quarters · filed 2026-02-26 | $43.04M derived: sum of 3 quarters · filed 2026-02-26 | $55.01M 10-K · filed 2026-02-26 |
| 2024-09-30 | $14.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $29.25M derived: sum of 2 quarters · filed 2025-11-04 | $41.21M 10-Q · filed 2025-11-04 | $52.11M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $14.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $26.31M 10-Q · filed 2025-08-11 | $37.21M derived: sum of 3 quarters · filed 2026-02-26 | $48.86M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $11.97M 10-Q · filed 2025-05-09 | $22.87M derived: sum of 2 quarters · filed 2026-02-26 | $34.52M derived: sum of 3 quarters · filed 2026-02-26 | $45.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $10.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $22.55M derived: sum of 2 quarters · filed 2026-02-26 | $33.73M derived: sum of 3 quarters · filed 2026-02-26 | $43.12M 10-K · filed 2026-02-26 |
| 2023-09-30 | $11.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $22.84M derived: sum of 2 quarters · filed 2024-10-31 | $32.22M 10-Q · filed 2024-10-31 | $41.13M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $11.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $20.57M 10-Q · filed 2024-08-07 | $29.47M derived: sum of 3 quarters · filed 2025-02-27 | $38.55M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $9.38M 10-Q · filed 2024-05-02 | $18.29M derived: sum of 2 quarters · filed 2025-02-27 | $27.37M derived: sum of 3 quarters · filed 2025-02-27 | $36.99M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $8.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $17.98M derived: sum of 2 quarters · filed 2025-02-27 | $27.61M derived: sum of 3 quarters · filed 2025-02-27 | $35.48M 10-K · filed 2025-02-27 |
| 2022-09-30 | $9.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $18.70M derived: sum of 2 quarters · filed 2023-11-02 | $26.57M 10-Q · filed 2023-11-02 | $35.25M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $9.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $17.50M 10-Q · filed 2023-08-03 | $26.17M derived: sum of 3 quarters · filed 2024-02-22 | $33.57M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $7.87M 10-Q · filed 2023-05-04 | $16.55M derived: sum of 2 quarters · filed 2024-02-22 | $23.95M derived: sum of 3 quarters · filed 2024-02-22 | $29.67M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $8.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $16.07M derived: sum of 2 quarters · filed 2024-02-22 | $21.80M derived: sum of 3 quarters · filed 2024-02-22 | $24.97M 10-K · filed 2024-02-22 |
| 2021-09-30 | $7.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $13.12M derived: sum of 2 quarters · filed 2022-11-03 | $16.29M 10-Q · filed 2022-11-03 | $18.12M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $5.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $8.90M 10-Q · filed 2022-08-09 | $10.72M derived: sum of 3 quarters · filed 2023-02-23 | $13.05M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $3.17M 10-Q · filed 2022-05-03 | $5.00M derived: sum of 2 quarters · filed 2023-02-23 | $7.33M derived: sum of 3 quarters · filed 2023-02-23 | $7.99M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $4.16M derived: sum of 2 quarters · filed 2023-02-23 | $4.82M derived: sum of 3 quarters · filed 2023-02-23 | $5.19M 10-K · filed 2023-02-23 |
| 2020-09-30 | $2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.99M derived: sum of 2 quarters · filed 2021-11-10 | $3.36M 10-Q · filed 2021-11-10 | $3.66M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $664.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $1.03M 10-Q · filed 2021-08-06 | $1.33M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | $371.00K 10-Q · filed 2021-05-06 | $668.00K derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $297.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.20M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $899.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |